Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bbce4df50f7f20ee2e179676d0700e2d8> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bbce4df50f7f20ee2e179676d0700e2d8 NCIT_P378 "NCI" @default.
- Bbce4df50f7f20ee2e179676d0700e2d8 type Axiom @default.
- Bbce4df50f7f20ee2e179676d0700e2d8 annotatedProperty IAO_0000115 @default.
- Bbce4df50f7f20ee2e179676d0700e2d8 annotatedSource NCIT_C7642 @default.
- Bbce4df50f7f20ee2e179676d0700e2d8 annotatedTarget "A disorder seen following cancer chemotherapy. It typically manifests a few years after initiation of epipodophyllotoxin chemotherapy. Mutagenic potential of these non-intercalating DNA topoisomerase II inhibitors is believed to be increased with concurrent use of asparaginase or granulocyte colony-stimulating factor. Balanced translocations involving chromosomal bands 11q23 and 21q22 are commonly associated with this disorder. Clinical signs may include fatigue, dyspnea, bruising and frequent infections. Clinical course usually progresses to acute myeloid leukemia though most epipodophyllotoxin-related leukemias do not have an antecedent myelodysplastic phase. Prognosis is dismal with survivability usually less than one year." @default.